This research study is trying to find out if REGN2810 (an anti-PD-1 antibody) is safe and effective at targeting the latent cells infected with HIV. If you join the study you will receive two doses of REGN2810 or placebo, one upon entry to the study and another 6 weeks later. They will be followed for 48 weeks.
While ART has been effective at suppressing HIV-1 in plasma to well below the limits of detection, low-level HIV-1 viremia persist in most patients. In patients who are effective treated with antiretrovirals, HIV-1 persists in latently infected resting CD4+ T-cells and possibily other issues or cellebular resevoirs. Elimination of latently infected cells with replication competent virus is necessary to cure HIV-1 infection.
One way that researchers are approaching this challenge is by addressing poor immune response caused by chronic HIV-1 infection, or "T-cell exhaustion," by administing an anti-PD-1 compound named cemiplimab.
For more information about the UCLA CARE Center's clinical trials and research studies, please contact: